Telix Pharmaceuticals
27 hedge funds and large institutions have $7.88M invested in Telix Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
29% more funds holding
Funds holding: 21 → 27 (+6)
8% more capital invested
Capital invested by funds: $7.29M → $7.88M (+$592K)
0.11% more ownership
Funds ownership: 0.13% → 0.24% (+0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.41M |
| 2 |
PIC
Portland Investment Counsel
Burlington,
Ontario, Canada
|
+$1.57M |
| 3 |
Lazard Asset Management
New York
|
+$1.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$936K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$595K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Pier Capital
Stamford,
Connecticut
|
-$3.04M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$975K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$668K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$217K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
-$19.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FFA
26
Farther Finance Advisors
San Francisco,
California
| $86 | +$110 | +9 | New |
|
|
TWD
27
True Wealth Design
Akron,
Ohio
| $29 | -$86 | -7 | -70% |
|
|
PC
28
Pier Capital
Stamford,
Connecticut
| – | -$3.04M | -188,992 | Closed |
|
|
29
Russell Investments Group
London,
United Kingdom
| – | -$975K | -60,301 | Closed |
|
|
30
Citadel Advisors
Miami,
Florida
| – | -$668K | -41,328 | Closed |
|
|
31
William Blair & Company
Chicago,
Illinois
| – | -$217K | -13,500 | Closed |
|
|
32
Raymond James Financial
St Petersburg,
Florida
| – | -$19.3K | -1,200 | Closed |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -141 | Closed |
|
|
JWA
34
JFS Wealth Advisors
Hermitage,
Pennsylvania
| – | -$434 | -27 | Closed |
|
TLX Hedge Fund Activity: Q3 2025 in Review
27 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Telix Pharmaceuticals (TLX) for Q3 2025, worth a combined $7.88M — up 8.1% from $7.29M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TLX positions and 7 closed out — a net gain of 6 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.41M. The largest seller was Pier Capital, exiting entirely with an estimated $3.04M sold.
- 27 institutional investors held Telix Pharmaceuticals (TLX) as of Q3 2025, up from 21 in Q2 2025.
- Funds reported $7.88M of Telix Pharmaceuticals stock for Q3 2025, up 8.1% quarter-over-quarter.
- 13 funds opened new Telix Pharmaceuticals positions in Q3 2025 and 7 closed out, a net change of +6 holders.
- The largest Telix Pharmaceuticals buyer in Q3 2025 was Millennium Management, an estimated $2.41M added.
- The largest Telix Pharmaceuticals seller in Q3 2025 was Pier Capital, an estimated $3.04M sold.
Based on aggregated 13F filings for Q3 2025.